Tizona Therapeutics, Inc., is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases.
Founded by MPM Capital and leading scientists from Dana Farber Cancer Institute, the University of Pittsburgh, Johns Hopkins, Memorial Sloan Kettering Cancer Center, and Brigham and Women’s Hospital, Tizona’s therapies are designed to modulate the activity of immunosuppressive cells, thereby activating the body’s ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases. Our programs target the cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment and for controlling self-reactivity in autoimmunity.
For more information, please email info@tizonatx.com.
Founded by MPM Capital and leading scientists from Dana Farber Cancer Institute, the University of Pittsburgh, Johns Hopkins, Memorial Sloan Kettering Cancer Center, and Brigham and Women’s Hospital, Tizona’s therapies are designed to modulate the activity of immunosuppressive cells, thereby activating the body’s ability to fight cancer or preventing the immune system from attacking healthy tissues in autoimmune diseases. Our programs target the cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment and for controlling self-reactivity in autoimmunity.
For more information, please email info@tizonatx.com.
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $343M
Founded date: 2015
Investors 6
| Date | Name | Website |
| 18.05.2023 | MPM Capita... | mpmcapital... |
| - | InterWest ... | interwest.... |
| - | Lightstone... | lightstone... |
| - | Abingworth... | abingworth... |
| - | MPM BioImp... | mpmbioimpa... |
| - | Canaan Par... | canaan.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 21.07.2020 | - | $300M | - |
| 08.03.2016 | Series B | $43M | - |
Mentions in press and media 8
| Date | Title | Description |
| 26.08.2020 | Tizona completes spinout of cancer program as part of Gilead buyout; Dyne files for $100M IPO | Tizona has completed the spinout of a new company that will focus on developing its now-former lead program involving an anti-CD39 antibody. The new company, Trishula Therapeutics, is designed to further progress an... |
| 09.03.2016 | Tizona signals full court press against regulatory T cells with $43M series B | - |
| 08.03.2016 | Tizona Therapeutics, Inc., Completes $43 Million Series B Financing | Proceeds will be Used to Advance Company's Immunotherapy Programs SOUTH SAN FRANCISCO Calif., March 8, 2016 -- Tizona Therapeutics, Inc., a privately held immunology company harnessing the power of the immune system to develop treatments fo... |
| 08.03.2016 | TIZONA THERAPEUTICS, INC., COMPLETES $43 MILLION SERIES B FINANCING | - |
| 08.03.2016 | Tizona Therapeutics Closes $43M Series B Funding | Tizona Therapeutics, Inc., a South San Fransico, CA-based immunology company leveraging the immune system to develop treatments for cancer and autoimmune diseases, closed a $43m Series B funding. The round was co-led by Abingworth and Canaa... |
| 08.03.2016 | Amgen Backs Tizona Therapeutics In $43M Funding | Thousand Oaks-based Amgen has made another investment this morning in immunology startup Tizona Therapeutics, via its venture capital arm, Amgen Ventures. According to Tizona Therapeutics, it completed a $43M Series B financing round, which... |
| 08.03.2016 | Tizona Therapeutics Grabs $43M | SAN FRANCISCO, CA, Tizona Therapeutics, a company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases, today announced the closing of a $43 million Series B financing. >> Click here fo... |
| 08.03.2016 | Tizona Therapeutics, Inc., Completes $43 Million Series B Financing | - |